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The intranasal dexmedetomidine plus
ketamine for procedural sedation in
children, adaptive randomized controlled
non-inferiority multicenter trial (Ketodex): a
statistical analysis plan
Anna Heath1,2,3* , Juan David Rios1, Eleanor Pullenayegum1,4, Petros Pechlivanoglou1,4, Martin Offringa1,4,5,
Maryna Yaskina6, Rick Watts6, Shana Rimmer6, Terry P. Klassen7,8, Kamary Coriolano9, Naveen Poonai10,11, on behalf
of the PERC-KIDSCAN Ketodex Study Group

Abstract
Background: Procedural sedation and analgesia (PSA) is frequently required to perform closed reductions for fractures
and dislocations in children. Intravenous (IV) ketamine is the most commonly used sedative agent for closed
reductions. However, as children find IV insertion a distressing and painful procedure, there is need to identify a
feasible alternative route of administration. There is evidence that a combination of dexmedetomidine and ketamine
(ketodex), administered intranasally (IN), could provide adequate sedation for closed reductions while avoiding the
need for IV insertion. However, there is uncertainty about the optimal combination dose for the two agents and
whether it can provide adequate sedation for closed reductions. The Intranasal Dexmedetomidine Plus Ketamine for
Procedural Sedation (Ketodex) study is a Bayesian phase II/III, non-inferiority trial in children undergoing PSA for closed
reductions that aims to address both these research questions. This article presents in detail the statistical analysis plan
for the Ketodex trial and was submitted before the outcomes of the trial were available for analysis.
Methods/design: The Ketodex trial is a multicenter, four-armed, randomized, double-dummy controlled, Bayesian
response adaptive dose finding, non-inferiority, phase II/III trial designed to determine (i) whether IN ketodex is noninferior to IV ketamine for adequate sedation in children undergoing a closed reduction of a fracture or dislocation in a
pediatric emergency department and (ii) the combination dose for IN ketodex that provides optimal sedation.
Adequate sedation will be primarily measured using the Pediatric Sedation State Scale. As secondary outcomes, the
Ketodex trial will compare the length of stay in the emergency department, time to wakening, and adverse events
between study arms.
(Continued on next page)
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Discussion: The Ketodex trial will provide evidence on the optimal dose for, and effectiveness of, IN ketodex as an
alternative to IV ketamine providing sedation for patients undergoing a closed reduction. The data from the Ketodex
trial will be analyzed from a Bayesian perspective according to this statistical analysis plan. This will reduce the risk of
producing data-driven results introducing bias in our reported outcomes.
Trial registration: ClinicalTrials.gov NCT04195256. Registered on December 11, 2019.
Keywords: Procedural sedation and analgesia, Pediatric closed reduction, Intranasal ketodex, Non-inferiority trial,
Bayesian adaptive design, Statistical analysis plan

Background
Orthopedic injuries are common in children visiting the
emergency department (ED) [1, 2], sometimes requiring
a closed reduction [3, 4], which usually requires procedural sedation and analgesia (PSA). Intravenous (IV) ketamine is a common sedative agent that facilitates closed
reductions [5]. However, IV insertion is distressing for
children and their caregivers and can be challenging as
children have small veins and resist positioning [6].
Intranasal (IN) administration of sedative agents is a
less invasive potential alternative to IV insertion [7] with
a combination of dexmedetomidine and ketamine (ketodex) showing promise for PSA across several indications
[8]. However, it is unclear whether IN ketodex would
offer sufficient analgesia and sedation for closed reductions in children with orthopedic injuries, compared to
IV ketamine, and there is no evidence on the most effective combination of dexmedetomidine and ketamine
within the ketodex formulation.
The intranasal dexmedetomidine plus ketamine for
procedural sedation in children (Ketodex) study aims to
determine (i) whether the sedation provided by IN ketodex is non-inferior to that provided by IV ketamine for
children undergoing a closed reduction and (ii) the combination dose of IN ketodex that provides optimal sedation. To achieve these objectives, the Ketodex study
uses an innovative Bayesian response-adaptive,
comparative-effectiveness design [9]. This paper outlines
the statistical analysis plan (SAP) for the Ketodex trial as
the study protocol is published separately [10]. This SAP
has been published before analyzing any study data and
follows the reporting guidelines for SAPs [11].

sedation characteristics of IN ketodex with respect to
length of stay in the ED, need for additional sedation,
nasal irritation, satisfaction with sedation, and adverse
events.

Methods/design
Design and setting

The Ketodex trial is a phase II/III, double-dummy, controlled, randomized, Bayesian response adaptive, dose
finding, non-inferiority trial being conducted in six Canadian tertiary care pediatric EDs. Eligible participants are
age 4 to 17 years and require PSA to undergo a closed
reduction of a fracture or dislocation. Following informed consent, patients will be randomized in a 2:3 ratio to receive either IV ketamine, dosed at 1.5 mg/kg
(maximum 100 mg), with an IN placebo combination
treatment, or one of three combination doses of IN
ketodex, i.e., 2, 3, or 4 mg/kg (maximum 400 mg) of
ketamine combined with 4, 3, or 2 μg/kg (maximum
200 μg) of dexmedetomidine, respectively, with an IV
placebo. Patients will then be further randomized to receive one of the three dose combinations, initially in a 1:
1:1 ratio (see “Randomization”).
Most study data will be collected in the ED within 1–
2 h of study enrollment. A follow-up phone call will be
made between 24 and 48 h after enrollment to collect
data on issues with the sedation. If a participant is lost
to telephone follow-up, a research nurse will attempt to
regain contact 3–5 times, using email or a letter to the
participant’s last known address, depending on local research ethics board (REB) regulations.
Study protocol development and conduct

Objectives

The primary aim of the Ketodex study is to determine if
IN ketodex is non-inferior to IV ketamine with respect
to the proportion of participants who achieve adequate
sedation for the duration of a closed reduction. We will
enroll previously healthy children who present to one of
six Canadian participating pediatric EDs requiring a reduction for a fracture or dislocation. The secondary objectives of the study are to determine the optimal
combination dose for IN ketodex and to characterize the

The Ketodex study was registered on ClinicalTrials.gov
on December 11, 2019, with registration number
NCT04195256. At each institution, the REB will give
ethical approval before commencing local enrollment.
Informed consent, following institutional REB guidelines,
will be obtained from caregivers before randomization
and data collection. The Ketodex study will be supported
by the KidsCAN-PERC iPCT network [12], a Canadian
trials network using centralized infrastructure for data
management and trial oversight for four trials. An
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independent data and safety monitoring board (DSMB)
of six oversees the study.
Randomization

Participants will be randomized in a ratio of 2:3 to either
IV ketamine or IN ketodex using block randomization
with blocks of size five, stratified by site. Participants will
undergo a further randomization to one of the three IN
ketodex combinations using the REDCap electronic data
capture system [13]. For participants randomized to IV
ketamine, the second randomization will be to two placebo (saline) solutions. The second randomization step
will be adapted so more participants receive the more effective dose combinations. Figure 1 displays this twostep randomization procedure.
The initial randomization ratio for the dose combinations will be 1:1:1. Interim analyses will update the
randomization ratio at approximately 150, 200, 250, 300,
and 350 participants. As outlined in the “Analysis for the
primary endpoint” section, each interim analysis will
compute the posterior probability that each dose is the
most effective. The number of patients randomized to
each dose before the next interim analysis will equal this
posterior probability multiplied by the number of participants to be enrolled before the next interim analysis,
rounded to the nearest whole number. If, at a given interim analysis, the probability that a dose is optimal falls
below 0.05 (threshold chosen by simulation), we will not
randomize participants to this dose. If all three combinations have a probability of being the most effective of
less than 50% once 250 participants have been enrolled,
then safety and tolerability will be assessed to determine
the most promising combination. This dose combination
will be used for all participants randomized to IN
ketodex.
The randomization list for the first step will be generated and held securely at the Women and Children’s

Fig. 1 Depiction of the randomization procedure for the Ketodex trial
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Health Research Institute’s (WCHRI) Data Coordinating
Centre at the University of Alberta [14]. Pharmacies will
prepare identically appearing IV ketamine plus IN saline
or IN ketodex plus IV saline kits for use at the bedside.
The second randomization will take place at the bedside
from a master randomization list, accessed sequentially
as participants are enrolled across all sites. Site-level
stratification is not used for the second randomization.
The research nurse will be blinded to the intervention
but not to the dose combination. Outcome assessors will
be blinded to the dose combination and the
intervention.

Data storage and collection

All participant data will be stored in REDCap [13] and
held at the WCHRI Data Coordinating Centre [14]. All
data will be entered into REDCap using a WiFi-enabled
encrypted iPad or recorded on paper in the event of a
technical failure. Prior to analysis, all personal identifiers
will be removed and participants will be identified using
a unique study identification number.

Primary outcome

The primary outcome is adequate sedation for the duration of the closed reduction. This will be ascertained
over the interval of time from the first application of
traction or manipulation of the injured limb for the purpose of anatomical realignment to the last application of
a realigning force. Adequate sedation is defined as fulfillment of all three of the following criteria:
i) A Pediatric Sedation State Scale (PSSS) [15] score
of 2 or 3 for the duration of the procedure AND
ii) No additional medication given during the closed
reduction for the purpose of sedation AND
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iii) The patient did not actively resist, cry, or require
physical restraint for completion of the closed
reduction.
The primary outcome will be assessed by two independent outcome assessors blinded to the study group
and objectives who will use video recordings of the
closed reduction to calculate the PSSS score every 30 s
during the procedure. Video scoring for each participant
will be undertaken within 24–48 h of data collection.
The second outcome assessor will score 25% of the participants to generate an interrater agreement.
Secondary efficacy outcomes

The Ketodex trial will investigate three secondary
outcomes:
1. Length of stay: Time (in minutes) recorded in the
medical record between ED triage and ED
discharge.
2. Time to wakening: This is the time interval between
the first pair or IN sprays to the first PSSS score > 3
post-closed reduction.
3. Adverse events (AEs): The occurrence of any AE,
recorded using the medical record and queries of
the health care staff during sedation and recovery.
Research nurses will be trained on the recognition
and definition of expected and unexpected AEs.
AEs will be based on Health Canada reporting
standards.
Additional outcomes

The Ketodex trial will record seven additional outcomes:
1) Length of stay due to PSA: Time (in minutes) from
the first pair of IN sprays/IV dose to ED discharge.
2) Duration of procedure: Time (in minutes) of the
first pair of IN sprays/IV dose to the end of cast or
splint application (closed reduction).
3) Length of ED stay: time interval between triage
assessment and discharge.
4) Caregiver, participant, bedside nurse or respiratory
therapist, and physician satisfaction: Satisfaction
from the caregiver and participant, measured using
a 100-mm visual analog scale, obtained immediately
prior to discharge. Satisfaction from each health
care provider, measured using a 100-mm visual analog scale immediately following cast/splint
application.
5) Nasal irritation: Discomfort associated with nasal
sprays (if recalled), assessed by the research nurse
using the Faces Pain Scale - Revised at discharge
[16].
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6) Volume of intervention: the volume of IN
intervention a patient received, compared to the
volume of IN intervention they were calculated to
receive, recorded at the index visit.
7) Adjunctive IV therapy and medications: the
requirement of an IV for therapy unrelated to
sedation.
8) Patient preference for the method of sedation: We
will ask the participant to choose their preferred
sedation method, if they have one, at the index visit
Sample size calculation

We used the average length criterion (ALC) for Bayesian
sample size estimation [17] by selecting the smallest
sample size such that the 95% high-density posterior
credible interval for the difference in the probability of
adequate sedation had an average length of 0.07, six
times shorter than the prior 95% highest-posterior density credible interval (“Analysis for primary endpoint”).
This reduction was selected based on practical constraints [17]. We also used ALC to determine the
randomization ratio between IV ketamine and IN ketodex; we considered randomizing 20%, 30%, 40%, and
50% of patients to IV ketamine.
The ALC initially selected the smallest sample size for
which the average length of the 95% high-density posterior credible interval fell below 0.07 and then selected the
randomization ratio that led to the most balanced trial,
provided the ALC remained below 0.07. We simulated
2000 samples from the prior predictive distribution of
the data, across all four randomization regimes, for sample sizes increasing from 350 to 500 in increments of 10.
For each simulation, we estimated the length of the 95%
high-density posterior credible interval using 2000 simulations from the posterior. Based on this, the sample size
for the Ketodex trial is 410 patients with a 2:3
randomization ratio between IV ketamine and IN
ketodex.
We expect minimal missing data as the primary outcome is collected during a procedure that must be completed by the physician before discharge. Thus, the
sample size is not adjusted for loss to follow-up. We will
monitor missingness and adjust our recruitment target
to ensure that 410 patients record the primary outcome.
Interim analysis and stopping guidance

The Ketodex trial will have seven interim analyses, at increments of 50 enrolled participants. The DSMB will review safety outcomes DSMB at each interim analysis
based on descriptive statistics of the safety outcomes between treatment groups. They may also receive posterior
credible intervals or predictive probabilities. The decision to stop the trial for safety reasons is at the discretion of the DSMB. Due to the uneven treatment
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allocation, the DSMB will be unblinded to treatment assignment. The randomization ratio at the 2nd level of
randomization will be updated after recruitment hits approximately 150, 200, 250, 300, and 350 participants. We
will not undertake comparative effectiveness analyses at
the interim analyses or stop for efficacy or futility.
Statistical analysis plan
Statistical principles

The primary analysis of the primary outcome will take
place after every participant has completed the protocol
and all data have been collected and cleaned. The statistical analysis will be performed unblinded to participant
allocation. The primary analysis will determine if the optimal IN ketodex combination is non-inferior to IV ketamine. All other analyses will test for superiority of IN
ketodex. We will undertake an intention-to-treat analysis, including all randomized participants, and a perprotocol analysis, concluding non-inferiority if both
these analyses confirm non-inferiority.
All analyses will use a Bayesian perspective with significance declared based on the posterior probability that
the proposed hypothesis is true. No adjustments will be
made for multiplicity due to the likelihood principle [18]
with the thresholds for declaring significance chosen
using simulations to control the type I error of the trial
[9]. Specifically, if this probability is less than 3.7%, we
will declare sufficient evidence against the hypothesis. If
the probability is greater than 60.8%, we will declare significant evidence for the hypothesis. If this probability is
between 3.7% and 60.8%, we will declare that the trial is
inconclusive. We will report treatment effect estimates
using 95% highest-density posterior credible intervals.
The statistical analysis will be undertaken in R [19] as an
interface to JAGS [20].
Handling of missing data

We anticipate minimal missing data as the majority of
outcomes are collected within the ED. If the proportion
of missing data is below 5%, we will undertake a
complete case analysis. If the level of missingness exceeds 5%, we will use a joint Bayesian model for the
missingness and the outcome.
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of participants lost to follow-up will be summarized by
treatment arm.
Protocol deviations and adherence

A protocol deviation is any noncompliance with the clinical trial protocol, International Conference on
Harmonization Good Clinical Practice, or Trial Manual
of Procedures requirements. Any change, divergence, or
departure from the study design or procedures constitutes a protocol deviation. The noncompliance may be
on the part of either the participant, the participating
site investigator, or the study site staff. The proportion
of protocol deviations will be presented by the treatment
group alongside descriptive information about the deviation. Adherence will be defined as a participant who received any of the study medications and will be
presented by the treatment group.
Baseline characteristics

We will collect the participants’ age and sex, type of
fracture or dislocation, location of fracture or dislocation, the identity of the person performing the closed reduction and, if required, the identity of the person
performing the casting. Baseline data will be summarized
using frequencies and percentages for categorical variables and means, medians, standard deviations, and
interquartile ranges for continuous variables.
Analysis for the primary endpoint

Interim analyses The adaptive randomization will be
based on the probability of adequate sedation for each
dose, denoted pi, i = 1, 2, 3. We assume a binomial likelihood for the data and a beta prior with parameters 6.25
and 0.25 for each dose. This prior is informed by previous data [21] and then down-weighted by 4 to an effective sample size of 6.5 [22]. Using the same prior for all
three doses assumes they have the same effectiveness
unless the data indicate otherwise. This prevents early
stopping of a dose combination. We will compute the
probability that each dose combination has the highest
proportion of successfully sedated participants from the
posterior distributions for pi, i = 1, 2, 3. This procedure
has an 83% chance of randomizing the highest number
of patients to the optimal treatment [9].

Patient flow

We will present patient flow with a CONSORT 2010
flow diagram reporting the number of participants
deemed eligible for the trial at screening and those excluded as they met a study exclusion criterion and the
number of participants who were randomized and received the randomized allocation. Participants can withdraw from the study at any time, for any reason. The
number of participants who withdraw and the number

Dose response modeling Participants who are not adequately sedated can be over-sedated (PSSS score of 0 or
1) or under-sedated (PSSS score of 4 or 5) [15]. The final
analysis will use a monotonic log-logistic dose response
model for the probability of over- and under-sedation
[23] and a multinomial distribution to infer the probability of adequate sedation. Specifically, let Xi, for i = 1, 2, 3,
be a three-vector containing the number of patients who
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experience under-, adequate, and over-sedation from the
Ni patients that receive dose i. We model Xi~Multinoð1Þ

ð2Þ

ð3Þ

mial(Ni, pi), where pi ¼ ðpi ; pi ; pi Þ and
ð1Þ


¼ logit β1 þ β2 logðK i Þ þ β3 logðDi Þ ;

ð3Þ


¼ logit βa þ βb logðK i Þ þ βc logðDi Þ ;

pi
pi

with Ki the dose of IN ketamine and Di the dose of IN
dexmedetomidine in the Ketodex combination. Interactions cannot be estimated accurately and are not required in dose finding studies [24]. The optimal dose
combination is the dose with the highest expected probability of adequate sedation.
Priors for the dose response model We will use noncentral t distributions with precision 0.001 and degrees
of freedom 1, suggested by [25]. The mean of β1 and βa
assume that 5% of participants are under-sedated and
ð2Þ

2% over-sedated, setting the prior means for pi ; i ¼ 1; 2
; 3 to 0.93, the effectiveness from the literature [21]. The
priors for β2, β3, βb and βc are centered on 0 so all dose
combinations initially have the same effectiveness.
Effectiveness analysis The primary effectiveness analysis will determine whether IN ketodex is non-inferior
to IV ketamine in terms of providing adequate sedation.
This analysis compares the effectiveness of IV ketamine
and the optimal IN ketodex combination. The probability of adequate sedation with IV ketamine (pIV) is estimated using a binomial likelihood and a beta prior
distribution with parameters 15.1 and 0.4. These prior
parameters are estimated from published data [26] and
down-weighted to prevent significant impact on the trial
results.
The primary analysis is based on the posterior probability that IN ketodex is non-inferior to IV ketamine.
γ = P( pIV − pIN > η),
where η = 0.178 is the non-inferiority margin, estimated from our team’s survey of 204 ED physicians
(outlined in the supplementary material), and pIN is the
probability of adequate sedation for the optimal IN ketodex combination. We will declare that IN ketodex is
non-inferior to IV ketamine if γ ≤ 0.037. Other values of
γ will induce alternative conclusions. This decision rule
based on γ has a type I error of 5% when pIV = 0.97 and
pIN = 0.792 and a type II error of 7% when pIN = 0.9 [9].
Analysis for secondary endpoints

Secondary outcomes For length of stay, onset of sedation, and duration of sedation, we will use a linear
dose-response model to estimate the mean duration for
the optimal IN ketodex combination. Distributional

assumptions for this model will be assessed using posterior predictive checks [27]. If a normal distribution is not
suitable, alternative model functions, e.g., gamma and
log-normal, will be considered. For IV ketamine, we will
estimate the mean length of stay, onset of sedation, and
duration of sedation by fitting a suitable distribution,
chosen using posterior-predictive checks. The comparison of the means will then determine the probability
that IN ketodex is superior to IV ketamine and declare
significance using the algorithm outlined above.
To analyze the AEs, we will use a logistic doseresponse model for IN ketodex and a binomial distribution for IV ketamine. We will then compute the posterior probability that optimal dose for IN ketodex has a
lower AE rate than IV ketamine, declaring significance
using the algorithm above. Each AE will be counted
once for a given participant. We will also report the severity, frequency, and relationship of AEs to the study
intervention by System Organ Class and preferred term
groupings. For each AE, we will also report the start
date, stop date, severity, relationship, expectedness, outcome, and duration. AEs leading to premature discontinuation from the study intervention and serious
treatment-emergent AEs will be presented in either a
table or a list.
Priors for secondary analyses Priors for the model intercepts will be obtained from the literature, where possible, and down-weighted to reduce prior influence on
the results. Priors for the regression coefficients will be
central t distributions with precision of 0.001 and degrees of freedom 1 [25]. Priors for the standard deviations will use non-central t distributions (truncated at 0)
[28]. We will ensure that these priors are vague with respect to the scale of the observed data and undertake
sensitivity analyses to the prior specification.
Additional outcomes

We will report additional outcomes with descriptive statistics, using frequencies and percentages for categorical
variables and means, medians, standard deviations, and
interquartile ranges for continuous variables.
Additional analyses

We will use logistic regression to investigate the interaction between baseline pain, measured using the Faces
Pain Scale - Revised, considered as a continuous variable, and treatment effect. The model will have a coefficient for treatment, baseline pain, and an interaction
term between treatment and baseline pain. This analysis
will only use data from the optimal dose combination.
We will conclude a significant interaction effect if the
95% credible interval for the treatment interaction does
not include zero.
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Trial status
The Ketodex study was registered on December 11,
2019, and started recruitment in March 2020. Recruitment is expected to be completed by December 2022.
For the final analysis, the database will be cleaned and
checked for completeness before being locked and the
statistical analysis will then be undertaken using the
methods in this SAP.

Ethics approval and consent to participate
Ethics approval was obtained from Clinical Trials Ontario for the lead site
(Children’s Hospital, London Health Sciences Centre) and McMaster
Children’s Hospital. The other participating sites received institutional ethics
approval. All protocol amendments will be submitted for approval to Health
Canada before being communicated to each site and implemented only
after Health Canada and REB approval. We will obtain child assent and
caregiver consent from all trial participants as appropriate.
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